SALIOGEN THERAPEUTICS
SalioGen Therapeutics is a gene coding company that develops potentially curative therapies for patients with inherited disorders. Its Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.
SALIOGEN THERAPEUTICS
Industry:
Biotechnology Genetics Life Science Therapeutics
Founded:
2020-01-01
Address:
Burlington, Massachusetts, United States
Country:
United States
Website Url:
http://www.saliogen.com
Total Employee:
11+
Status:
Active
Contact:
(650) 906-9468
Total Funding:
135 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins Global Site Tag
Similar Organizations
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Parthenon Therapeutics
Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.
Ray Therapeutics
Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
SymBiosis LLC
SymBiosis LLC investment in Series B - SalioGen Therapeutics
D1 Capital Partners
D1 Capital Partners investment in Series B - SalioGen Therapeutics
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - SalioGen Therapeutics
Retinal Degeneration Fund
Retinal Degeneration Fund investment in Series B - SalioGen Therapeutics
GordonMD Global Investments
GordonMD Global Investments investment in Series B - SalioGen Therapeutics
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Series B - SalioGen Therapeutics
T. Rowe Price
T. Rowe Price investment in Series B - SalioGen Therapeutics
EPIQ Capital Group
EPIQ Capital Group investment in Series B - SalioGen Therapeutics
PBM Capital Group
PBM Capital Group investment in Series A - SalioGen Therapeutics
Official Site Inspections
http://www.saliogen.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago